BriaCell Therapeutics Corp. (NASDAQ:BCTX) to Post Q1 2025 Earnings of ($0.30) Per Share, HC Wainwright Forecasts

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of BriaCell Therapeutics in a research report issued on Thursday, October 3rd. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.17) EPS.

BriaCell Therapeutics Stock Up 2.5 %

Shares of NASDAQ:BCTX opened at $0.98 on Friday. The company’s fifty day moving average is $0.71 and its 200 day moving average is $1.38. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.16. The stock has a market cap of $18.00 million, a PE ratio of -0.79 and a beta of 1.34.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC boosted its position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned approximately 0.31% of BriaCell Therapeutics worth $143,000 at the end of the most recent quarter. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.